Brief: Avacta Group Reports Platform-Validating Data With Faridoxorubicin
Today 08:06
BRIEF-Avacta Group Reports Platform-Validating Data With Faridoxorubicin June 25 (Reuters) - Avacta Group PLC AVCT.L:
PLATFORM-VALIDATING DATA WITH FARIDOXORUBICIN
RESPONSES OBSERVED IN PATIENTS WITH VERY LOW FAP EXPRESSION DESPITE TUMOR RESPONSE
FURTHER DATA UPDATES EXPECTED IN Q3 2026
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Avacta
See all newsBrief: Avacta Group Reports Platform-Validating Data With Faridoxorubicin
Brief: Avacta Group Announces FDA Agreement On Pivotal Trial Design For Ava6000
FDA Agreement on Pivotal Trial Design for AVA6000
Platform-Validating Data with Faridoxorubicin
Brief: Avacta Therapeutics Appoints Richard Hughes As Non-Executive Chairman